In parallel, ctDNA provides a minimally invasive, dynamic readout of tumor burden and early treatment effect, with rapid declines in ctDNA levels after ICI initiation correlating with superior progression-free and overall survival (OS) independently of PD-L1 status or TMB [1,2,3,4]. Here, CD274 is linked to neoplasm.